Antibody-drug conjugates remain front and centre of the biopharma world. Following Enhertu’s historic agnostic approval in HER2-positive solid tumours and TIVDAK winning full approval, the field has ...
Improving Prediction & Translation of ADC Toxicities to Drive More Tolerable ADCs Successfully Into & Through Clinical Development Toxicities continue to pose the most significant challenge in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results